Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease
Viviane Tabar(Memorial Sloan Kettering Cancer Center), Claire Henchcliffe(University of California, Irvine), Stefan Irion(University Health Network), N. Abid, Kenny Yu(Memorial Sloan Kettering Cancer Center), Suneil K. Kalia(University Health Network), David Eidelberg(Northwell Health), Harini Sarva(Cornell University), Alfonso Fasano(University of Toronto), Lorenz Studer(Memorial Sloan Kettering Cancer Center), Andrés M. Lozano(University of Toronto), Antoine Lampron, Cameron Brennan(Memorial Sloan Kettering Cancer Center), W. Stemple, M. Tomishima, Shichun Peng(Feinstein Institute for Medical Research), Yilong Ma(Feinstein Institute for Medical Research)
Cited by 131
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Deep Brain Stimulation for Treatment-Resistant Depression
|Neuron|2005|4.1k
Molecular characterization of the tumor microenvironment in breast cancer
|Cancer Cell|2004|1.3k
Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
|Biological Psychiatry|2008|1k